While specifictreatments have been developed for ERα+ BC (tamoxifen, aromataseinhibitors) and HER2+ BC (trastuzumab), the only option for most TNBC patients iscytotoxic chemotherapy such as anthracyclines (doxorubicin), which leads to significantmorbidity. The gene discussed is ERBB2; the disease is breast cancer.